Zelda Therapeutics ("Zelda") has been established by a seasoned group of executives to focus on generating clinical data in several indications using medical cannabis based formulations. These formulations have already demonstrated efficacy in hundreds of patients over several years and Zelda has an exclusive, global license to this data. The company is working with several very high profile researchers and clinicians across the globe
The company conducts this work in partnership with world-renowned researchers and organisations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent’s Hospital in Melbourne, Australia; and the Children’s Hospital of Philadelphia (CHOP) in the United States
Zelda’s is targeting the most common indications treated with medicinal cannabis as reported by patients; namely pain, anxiety and sleep. Our strategy is to develop treatments based on plant-derived (ie. full spectrum) medicinal cannabis products that address the largest possible markets and have the greatest medical impact.
To achieve this, Zelda is bringing together the world’s leading researchers and clinicians working in the study and use of medicinal cannabis. The Company is undertaking:
- A human clinical trial programme focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.